Perspective Therapeutics Management

Management criteria checks 1/4

Perspective Therapeutics' CEO is Thijs Spoor, appointed in Feb 2023, has a tenure of 1.17 years. total yearly compensation is $1.46M, comprised of 34.7% salary and 65.3% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth $172.13K. The average tenure of the management team and the board of directors is 1.2 years and 1.2 years respectively.

Key information

Thijs Spoor

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage	34.7%
CEO tenure	1.2yrs
CEO ownership	0.02%
Management average tenure	1.2yrs
Board average tenure	1.2yrs

Recent management updates

Recent updates

We're Interested To See How Isoray (NYSEMKT:ISR) Uses Its Cash Hoard To Grow

Mar 19

CEO Compensation Analysis

How has Thijs Spoor's remuneration changed compared to Perspective Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$506k	-US$37m

Compensation vs Market: Thijs's total compensation ($USD1.46M) is below average for companies of similar size in the US market ($USD3.44M).

Compensation vs Earnings: Insufficient data to compare Thijs's compensation with company performance.

CEO

Thijs Spoor (51 yo)

1.2yrs

Tenure

US$1,458,996

Compensation

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Johan Spoor	CEO & Director	1.2yrs	US$1.46m	0.018% $ 172.1k
Jonathan Hunt	CFO & Co-Principal Financial Officer	5.3yrs	US$1.17m	0.054% $ 506.7k
Markus Puhlmann	Chief Medical Officer	1.2yrs	US$900.09k	0.23% $ 2.2m
Shane Cobb	Executive Vice President of Operations	less than a year	no data	no data
Mark Austin	VP of Finance	6.8yrs	no data	0.0092% $ 86.5k
Michael Schultz	Chief Science Officer	no data	no data	2.53% $ 23.7m
Andrew Bright	Executive Vice President of Brachytherapy	less than a year	no data	no data
Amos Hedt	Chief Business Strategy Officer	no data	no data	no data
Frances Johnson	Chief Innovation Officer	no data	no data	2.53% $ 23.7m
David Hauser	Senior Vice President of Clinical Operations	no data	no data	no data

1.2yrs

Average Tenure

53.5yo

Average Age

Experienced Management: CATX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Johan Spoor	CEO & Director	1.2yrs	US$1.46m	0.018% $ 172.1k
Robert Williamson	Independent Director	1.2yrs	US$320.06k	0.058% $ 547.9k
Frank Morich	Independent Director	1.2yrs	US$320.06k	no data
Heidi Henson	Independent Director	less than a year	US$390.70k	no data
Lori Holmes-Woods	Chairperson of the Board	5.8yrs	US$671.73k	0.27% $ 2.5m

1.2yrs

Average Tenure

57yo

Average Age

Experienced Board: CATX's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Perspective Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought US$140k worth of stock

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Recent updates

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought US$140k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Second quarter 2023 earnings released

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Chairperson of the Board exercised options to buy US$129k worth of stock.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Isoray, Inc. to Report Q4, 2022 Results on Sep 28, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Isoray, Inc. to Report Q3, 2022 Results on May 10, 2022

Price target decreased to US$1.47

Insufficient new directors

Consensus EPS estimates fall by 15%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CEO & Director exercised options to buy US$64k worth of stock.

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.016 loss per share (vs US$0.01 loss in 1Q 2021)

Price target decreased to US$1.63

American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131

Full year 2021 earnings released: US$0.033 loss per share (vs US$0.051 loss in FY 2020)

Third quarter 2021 earnings released: US$0.006 loss per share (vs US$0.008 loss in 3Q 2020)

We're Interested To See How Isoray (NYSEMKT:ISR) Uses Its Cash Hoard To Grow

CEO & Director exercised options to buy US$345k worth of stock.

Executive Vice President of Sales & Marketing Michael Krachon has left the company

Michael Krachon to Resign as Executive Vice President of Sales and Marketing of Isoray, Effective March 12, 2021

Isoray, Inc. Appoints Lisa Lauer as Vice President Business Development

CEO Compensation Analysis

CEO

Tenure